Month: December 2021

Merck has recently published a press release about the final analysis of the phase III trial KEYNOTE-240 (“type”:”clinical-trial”,”attrs”:”text”:”NCT02702401″,”term_id”:”NCT02702401″NCT02702401) evaluating pembrolizumab placebo while second-line treatment in European population; even though co-primary endpoints OS and PFS were improved, these differences did not meet the statistical significance

hOT7T175 Receptor

December 4, 2021 unscburma

Merck has recently published a press release about the final analysis of the phase III trial KEYNOTE-240 (“type”:”clinical-trial”,”attrs”:”text”:”NCT02702401″,”term_id”:”NCT02702401″NCT02702401) evaluating pembrolizumab placebo while second-line treatment in […]

Continue reading

Orthotopic syngeneic TNBC mammary tumors showed decreased tumor burden in MIF KO mice in comparison to WT mice

Histamine H2 Receptors

December 2, 2021 unscburma

Orthotopic syngeneic TNBC mammary tumors showed decreased tumor burden in MIF KO mice in comparison to WT mice. within a syngeneic mouse model. We demonstrated […]

Continue reading

3D and E)

Human Leukocyte Elastase

December 1, 2021 unscburma

3D and E). Open in a separate window Fig. combination of the SOCE inhibitor SKF-96365 with autophagy inhibitors represents a promising strategy for treating patients […]

Continue reading